Alzheimer’s Researchers Discover Bryostatin Can Slow, Reverse Disease Progression

Alzheimer’s Researchers Discover Bryostatin Can Slow, Reverse Disease Progression
Alzheimer's researchResearchers from the Blanchette Rockefeller Neuroscience Institute (BRNI) have gathered evidence of the possible role of protein kinase C epsilon (PKCe) in the treatment of Alzheimer's disease (AD). The news was recently announced by Neurotrope, a pharmaceutical company collaborating with BRNI in the development of bryostatin, a potent modulator of PKCe, for the treatment of patients suffering with AD. One of the big challenges in treating AD is the fact that patients t
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *